People · Operator
Named in public records as an officer, director or promoter · active 2009–2018 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| BlinkBio, Inc. | — | Biotechnology | Series B | $43.6M | $20.8M | 2009 |
| Anagin, Inc. | — | Pharmaceuticals | Seed | $4.4M | $49.8M | 2016 |
| Scioto Biosciences, Inc. | — | Biotechnology | Seed | $1.8M | $80.9M | 2018 |
James Schulz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Schulz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Derek Small | 2 | 4 |
| Mark Simon | 1 | 6 |
| Geoff Smith | 1 | 6 |
| Colin Goddard | 1 | 5 |
| Douglas Reed | 1 | 4 |
| Alan Lewis | 1 | 4 |
| Nora Doherty | 1 | 3 |
| Kapil Dhingra | 1 | 2 |
| Mark Heiman | 1 | 2 |
| Jutta Wanner | 1 | 2 |
| Michael Gargano | 1 | 2 |
| Viren Mehta | 1 | 2 |
| Kevin Meyer | 1 | 1 |
| Maneesh Pingle | 1 | 1 |
| Frank French | 1 | 1 |
| Yvonne Lai | 1 | 1 |
| Anantha Shekhar | 1 | 1 |
| Jaswant Gidda | 1 | 1 |
| Joseph Trebley | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.